A consensus development conference model for establishing health policy for surveillance and screening of antimicrobial-resistant organisms

Clinical Infectious Diseases

Volumn 60, Issue 7, 2015, Pages 1095-1101

  Buick, Steve ^a   Joffe, A Mark ^b,c   Taylor, Geoffrey ^b,c   Conly, John ^b,d  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

antibiotic resistant organism; health policy; hospital acquired infection; screening; surveillance

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CANADA; CONSENSUS DEVELOPMENT; EMERGENCY CARE; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PUBLIC HEALTH; BACTERIAL INFECTIONS; CROSS INFECTION; DISEASE TRANSMISSION; EPIDEMIOLOGICAL MONITORING; MASS SCREENING; MICROBIOLOGY; MORTALITY; PREVENTION AND CONTROL; PROCEDURES;

BACTERIAL INFECTIONS; CANADA; CROSS INFECTION; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; HEALTH POLICY; HUMANS; INFECTION CONTROL; MASS SCREENING;

EID: 84926674297     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu1168     Document Type: Article

References (44)

1. Kunin CM. Perspective: resistance to antimicrobial drugs: a worldwide calamity. Ann Intern Med 1993; 118:557-61.
2. American Society for Microbiology. Report of the ASM Task Force on Antimicrobial Resistance. Antimicrob Agents Chemother 1995 (suppl): 1-23.
3. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
4. Nugent R, Back E, Beith A. A report of the Center for Global Development's Drug Resistance Working Group. Washington, DC: Center for Global Development, 2010.
5. Carlet J, Collignon P, Goldmann D, et al. Society's failure to protect a precious resource: antibiotics. Lancet 2011; 378:369-71.
6. Ndowa F, Lusti-Narasimhan M, Unemo M. The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. Sex Transm Infect 2012; 88:317-8.
7. World Health Organization. WHA58.27. Improving the containment of antimicrobial resistance. Ninth plenary meeting, 25 May 2005-Committee B, 4th report. 58th World Health Assembly. Available at: http://apps.who.int/gb/ebwha/pdf-files/WHA58-REC1/A58-2005-REC1-en.pdf. Accessed 10 October 2014.
8. World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Available at: http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 10 October 2014.
9. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/index.html. Accessed 10 October 2014.
10. Gardam MA. Is methicillin-resistant Staphylococcus aureus an emerging community pathogen?. A review of the literature. Can J Infect Dis 2000; 11:202-11.
11. Gilbert MJ, MacDonald J, Gregson D, et al. Outbreak in Alberta of community-Acquired (USA300) methicillin-resistant Staphylococcus aureus in people with a history of drug use, homelessness or incarceration. CMAJ 2006; 175:149-54.
12. Nimmo GR, CoombsGW, Pearson JC, et al. Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med J Aust 2006; 184:384-8.
13. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7:629-41.
14. Gould IM, David MZ, Esposito S, et al. New insights into meticillinresistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 2012; 39:96-104.
15. Stegger M, Wirth T, Andersen PS, et al. Origin and evolution of European community-Acquired methicillin-resistant Staphylococcus aureus. MBio 2014; 5:e01044-14.
16. Fluit AC. Livestock-Associated Staphylococcus aureus. Clin Microbiol Infect 2012; 18:735-44.
17. Fitzgerald JR. Livestock-Associated Staphylococcus aureus: origin, evolution and public health threat. Trends Microbiol 2012; 20:192-8.
18. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13:785-96.
19. Rogers BA, Sidjabat HE, Silvey A, et al. Treatment options for New Delhi metallo-b-lactamase-harboring Enterobacteriaceae. Microb Drug Resist 2013; 19:100-3.
20. Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-Type carbapenemases in gram-negative bacteria. Biomed Res Int 2014; 2014:249856.
21. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7:1401-22.
22. Lewis DA. Global resistance of Neisseria gonorrhoeae: when theory becomes reality. Curr Opin Infect Dis 2014; 27:62-7.
23. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-b-lactamase gene, Bla (NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53:5046-54.
24. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597-602.
25. Wenzel RP, Edmond MB. Infection control: the case for horizontal rather than vertical interventional programs. Int J Infect Dis 2010; 14(suppl 4):S3-5.
26. Henderson DK, Palmore TN. Critical gaps in knowledge of the epidemiology and pathophysiology of healthcare-Associated infections. Infect Control Hosp Epidemiol 2010; 31(suppl 1):S4-6.
27. Weinstein RA, Henderson DK. A double-edged sword and a golden opportunity for healthcare epidemiology. Infect Control Hosp Epidemiol 2009; 30:1-3.
28. Palmore TN, Henderson DK. Managing transmission of carbapenemresistant Enterobacteriaceae in healthcare settings: a view from the trenches. Clin Infect Dis 2013; 57:1593-9.
29. Office of Disease Prevention, US Department of Health and Human Services, National Institutes of Health. Consensus development program Available at: http://consensus.nih.gov/. Accessed 10 October 2014.
30. Institute of Health Economics. IHE's knowledge transfer program. Available at: http://www.ihe.ca/research/knowledge-Transfer-initiatives/. Accessed 10 October 2014.
31. Bond K, Tjosvold L, Harstall C. Effectiveness of screening for endemic antibiotic resistant organisms (AROs) in hospital settings. Summary of systematic reviews, primary studies, and evidence-based guidelines. In: Canadian Consensus Development Conference on Surveillance and Screening for AROs. Edmonton, AB: Institute of Health Economics, 2014. Available at: http://www.ihe.ca/publications/library/2014/. Accessed 10 October 2014.
32. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013; 368:2255-65.
33. Dobrow MJ, Goel V, Upshur REG. Evidence-based health policy: context and utilization. Soc Sci Med 2004; 58:207-17.
34. Guyatt GH, Oxman AD, Kunz R, et al. What is 'quality of evidence' and why is it important to clinicians?. BMJ 2008; 336:995-8.
35. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008; 336:1049-51.
36. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
37. Thacker SB, Ikeda RM, Gieseker KE, et al. The evidence base for public health informing policy at the Centers for Disease Control and Prevention. Am J Prev Med 2005; 29:227-33.
38. European Centre for Disease Prevention and Control. Technical report: evidence-based methodologies for public health-how to assess the best available evidence when time is limited and there is lack of sound evidence. Stockholm, Sweden: 2011. Available at: http://www.ecdc.europa. eu/en/publications/Publications/1109-TER-evidence-based-methods-for-public-health.pdf. Accessed 10 October 2014.
39. Plsek P, Greenhalgh T. Complexity science: the challenge of complexity in health care. BMJ 2001; 323:625-8.
40. Wertheim HF, Vos MC, Boelens HA, et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 2004; 56:321-5.
41. Bode LG, Wertheim HF, Kluytmans JA, et al. Sustained low prevalence of meticillin-resistant Staphylococcus aureus upon admission to hospital in the Netherlands. J Hosp Infect 2011; 79:198-201.
42. Traa MX, Barboza L, Doron S, Snydman DR, Noubary F, Nasraway Jr. SA. Horizontal infection control strategy decreases methicillin-resistant Staphylococcus aureus infection and eliminates bacteremia in a surgical ICU without active surveillance. Crit Care Med 2014; 42:2151-7.
43. Derde LP, Cooper BS, Goossens H, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 2014; 14:31-9.
44. Kouri D, Gagnon F. Two Canadian examples of 'whole-of-government' approaches. National Collaborating Centre for Healthy Public Policy. Available at: http://www.ncchpp.ca/147/presentations.ccnpps?id-Arti cle=90. Accessed 10 October 2014.